Source:
https://www.business-standard.com/article/news-cm/strides-receives-usfda-approval-for-tetracycline-hydrochloride-capsules-120030400252_1.html
https://www.business-standard.com/article/news-cm/strides-receives-usfda-approval-for-tetracycline-hydrochloride-capsules-120030400252_1.html
Strides Pharma Science announced that its step-down wholly owned
subsidiary, Strides Pharma Global, Singapore, has received approval for
Tetracycline Hydrochloride Capsules USP, 250 mg and 500 mg from the United
States Food & Drug Administration (USFDA).
The product is a generic version of Achromycin V Capsules, 250 mg and 500
mg, of Avet Pharmaceuticals Inc (previously Heritage Pharmaceuticals Inc.)
According to IQVIA MAT data, the US market for Tetracycline Hydrochloride
Capsules USP, 250 mg and 500 mg is approximately US$ 16 Mn. The product will be
manufactured at the company's flagship facility at Bangalore and will be
marketed by Strides Pharma Inc. in the US market.
